Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed MM
Status:
Recruiting
Trial end date:
2025-07-31
Target enrollment:
Participant gender:
Summary
A randomized Phase II clinical trial will be conducted to assess the impact on progression
free survival (PFS) with the addition of ixazomib and daratumumab to lenalidomide as a
maintenance treatment following induction with lenalidomide, ixazomib, dexamethasone, and
daratumumab.
Patients will be randomized to either:
Arm A: 12 cycles of lenalidomide, ixazomib, daratumumab, and dexamethasone followed by
lenalidomide until disease progression or unacceptable toxicity or a maximum of 2 years of
maintenance therapy.
Arm B: 12 cycles of lenalidomide, ixazomib, daratumumab and dexamethasone, followed by
lenalidomide, ixazomib, and daratumumab until disease progression or unacceptable toxicity or
a maximum of 2 years maintenance therapy.